Stock option grant for Q32 Bio Inc. (QTTB) director corrects prior award
Rhea-AI Filing Summary
Q32 Bio Inc. director David S. Grayzel received a corrected grant of stock options covering 10,826 shares of common stock at an exercise price of $12.64 per share, expiring on June 11, 2036.
The options vest in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Any proceeds from sales of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
GRAYZEL DAVID S.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2, F3 | 10,826 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,826 shares (Direct)
Footnotes (3)
- F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
- F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
- F3. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Key Figures
Stock options granted: 10,826 shares
Exercise price: $12.64 per share
Option expiration date: June 11, 2036
+1 more
4 metrics
Stock options granted
10,826 shares
Options to purchase common stock granted to director on June 12, 2026
Exercise price
$12.64 per share
Exercise price for the reported stock option award
Option expiration date
June 11, 2036
Expiration date of the granted stock options
Vesting trigger
Earlier of June 12, 2027 or next annual meeting
Full vesting contingent on continued service through the vesting date
Key Terms
Stock Option (Right to Buy), pecuniary interest, Section 16 of the Securities Exchange Act of 1934, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"The security title is listed as Stock Option (Right to Buy) for common stock."
pecuniary interest financial
"The Reporting Person disclaims ownership except to the extent of his pecuniary interest therein."
Section 16 of the Securities Exchange Act of 1934 regulatory
"Disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934."
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
annual meeting of stockholders regulatory
"Vests upon the earlier of June 12, 2027 or the date of the Issuer's next annual meeting of stockholders."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock option grant did Q32 Bio (QTTB) report for David S. Grayzel?
Q32 Bio reported that director David S. Grayzel received 10,826 stock options with an exercise price of $12.64 per share. The options relate to common stock and expire on June 11, 2036, representing a compensation award rather than an open-market trade.
Why was the Q32 Bio (QTTB) Form 4/A amendment filed?
The Form 4/A was filed to correct the number of options awarded to David S. Grayzel on June 12, 2026. The amendment states it is solely to fix that option amount from the earlier Form 4 submitted on June 16, 2026.
When do David S. Grayzel’s QTTB stock options vest?
The options will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders. Vesting is conditioned on Grayzel’s continued service through that vesting date.
Did the Q32 Bio (QTTB) Form 4/A show any open-market buys or sells of common stock?
No. The Form 4/A reports only a grant of stock options to director David S. Grayzel, with no open-market purchases or sales of Q32 Bio common stock reported in this amendment.